Galena’s Immunotherapy GALE-301 Shows Promise in Preventing Ovarian Cancer Recurrence

Galena’s Immunotherapy GALE-301 Shows Promise in Preventing Ovarian Cancer Recurrence
The cancer immunotherapy GALE-301 is a promising therapeutic approach to prevent cancer recurrence in women with ovarian and endometrial cancers who underwent surgery, according to data from the final analysis of a Phase 1/2a trial. Two years after undergoing surgery, 77% of women receiving the optimal dose of GALE-301 in the trial remained disease-free, compared with 44% of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *